Eclipsebio’s eVERSE provides access to AI-ready data from their comprehensive portfolio of next-generation sequencing technologies, including measurements of RNA secondary structure, protein translation, and regulatory regions.
Eclipsebio’s partners can improve AI-powered drug discovery with reproducible and high-quality data capturing key determinants of siRNA, ASO, and mRNA-based therapy efficacy.
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design. Eclipsebio will reveal eVERSE at the Computational RNA Design & Delivery Summit on June 25, 2025.
“Artificial intelligence and machine learning are the future of developing life-saving therapies, yet a major challenge for their use is obtaining high-quality and reproducible data,” said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. “eVERSE is a one-of-a-kind portfolio of training datasets generated directly by our team of RNA biologists at Eclipsebio. These validated datasets provide the direct measurements needed to develop safe and effective small oligonucleotide, small molecule and RNA-based therapies.”
eVERSE provides actionable, multidimensional training data from Eclipsebio’s full suite of next-generation sequencing technologies. These include measurements of RNA secondary structure, protein translation, RNA regulatory regions, and base modifications. As the exclusive provider of these assays in the United States, Eclipsebio’s eVERSE provides partners with training data that is not available anywhere else. In addition to ready-to-download datasets, partners can also obtain custom datasets from specific cell lines, tissues, or disease conditions.The post Eclipsebio Announced the Launch of eVERSE™ first appeared on AI-Tech Park.